Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies

(NASDAQ:CBTX) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics, today announced dosing of the first participant in its CROSSCHECK-001 Phase 1 clinical trial of CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid malignancies. “Patients with relapsed or refractory myeloid malignancies urgently need new treatment options, and CBX-250 offers a novel